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The purpose of this symposium was to consider
the new approaches to the management of serious
infections of hospitalised patients. The sympo-
sium focused on two areas, febrile neutropenic
patients and ventilator-associated pneumonia.
However, the issues of antibiotic resistance are
relevant for many other areas in the hospital.
One of the major issues facing the treating
physician is the lack of new drug development.
This is especially true for the Gram-negative
bacilli. For various reasons, the number of drugs
being developed has been sharply reduced over
the past few years. This reduction has led to a
more urgent need for clinicians to learn to do
more with what they have. The various partici-
pants in this symposium have therefore provided
help for the clinician to do more with the drugs
we have available.
Dr Peterson pointed out that increased drug
usage, with resulting increased exposure, can be
expected to lead to resistance. While this has been
far more rapid with some antibiotics, such as
cephalosporins and ﬂuroquinolones, one could
expect it with all antibiotics. In one study, the use
of imipenem as a replacement for a cephalosporin
was associated with high levels of resistance for
Pseudomonas aeruginosa within a year [1]. In some
ways, this can be compared to squeezing a
balloon; restricting one antibiotic leads to another
antibiotic losing its effectiveness [2]. However,
prolonged use of piperacillin–tazobactam for
empirical treatment has not been associated with
the same rapid rate of emerging resistance.
Aminoglycosides are another example of antibi-
otics which lead to resistance only after prolonged
exposure. However, switching from gentamicin to
tobramycin led to recovery of the effectiveness of
gentamicin [3]. The use of the piperacillin–tazo-
bactam or an aminoglycoside for empirical ther-
apy may allow one to resuscitate some of the
other antibiotics.
Dr Glasmacher has demonstrated how meta-
analysis allows for pooling information from
previous studies. This enables the clinician to
answer questions which were not apparent from
individual studies. For example, meta-analysis of
studies of the febrile neutropenic patient demon-
strated that monotherapy was safer than combi-
nation therapy with aminoglycoside. In addition,
monotherapy was at least as effective. Although
recommendations from such studies are useful,
they may not apply at a particular hospital. If
there is a large problem with multidrug resist-
ance, aminoglycosides may still be needed for
treatment of neutropenic fever. However, the
clinician has the evidence to support the use of
monotherapy for the majority of patients with
neutropenic fever [4].
Dr Bow also used meta-analysis to compare
new study results with those of prior trials. He
showed the beneﬁts of combined analysis; these
included demonstration that the failure rates of
some of the new therapies may be as high as those
found in prior studies. However, he pointed out
that the overall mortality was lower with current
therapy. This demonstrates that before one chan-
ges empirical therapy, one has to be sure which
outcome is most important. He proposed mortal-
ity as the standard to evaluate therapy.
The importance of knowledge of local ﬂora was
discussed by Dr Bow. Fluoroquinolones have
been found to be useful in some studies in
preventing neutropenic fever. Analysis of studies
to date demonstrates that this strategy is effective
as long as the rate of Gram-negative bacillary
resistance is less than 10%. If the rate of resistance
is higher, then there is no advantage with ﬂuor-
oquinolone therapy.
The outcome of ventilator-associated pneu-
monia (VAP) is also affected by the rise of
multidrug-resistant bacteria. The three most com-
mon bacteria causing VAP are Staphylococcus
aureus, P. aeruginosa, and Acinetobacter baumannii
[5]. All of these are associated with increasing rates
of resistance. Antibiotic strategies must include
ways in which to reduce the rate of resistance
during therapy. In addition, the effects of antibiotic
therapy on other bacteria need to be considered.
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Dr Rello discussed the need for aggressive
empirical therapy for VAP. Several studies have
shown that inadequate initial therapy is associ-
ated with increased mortality [6,7]. Dr Rello
described the approach developed at his institu-
tion to manage VAP [8]. In addition to aggressive
initial therapy, he obtains a lower respiratory tract
specimen for culture. This microbiological infor-
mation is available 3 days after starting therapy.
Armed with this information, the clinician can
narrow the treatment as needed. A recent study
demonstrated that one can reduce the number of
antibiotic days in patients with VAP due to
organisms other than P. aeruginosa. The reduced
number of days of therapy was associated with a
lower rate of superinfection with resistant organ-
isms [9].
Table 1 emphasises the evolution of treatment
protocols of empirical therapy for neutropenic
fever and VAP. The old model was developed
when it was realised that there was a high
mortality rate due to the delay inherent in waiting
for the results of culture. Patients at risk for
infection were started on empirical therapy. This
resulted in a lower mortality rate than when
treatment was postponed until blood or sputum
culture results were available. The choice of
empirical therapy was usually broad spectrum.
Several potential agents were available, and local
preferences were often dictated by prior experi-
ence. Cost was not considered an issue. Given the
increasing cost of healthcare, many guidelines
were developed to simplify care and reduce costs.
The use of guidelines for empirical therapy did
not usually result in signiﬁcant differences
between various antibiotic trials. The choice of a
speciﬁc agent was then based on cost. The overall
effectiveness of the antibiotic at an individual
institution was not considered. In addition,
secondary problems, such as increased toxicity
or the need for monitoring drug levels, were
usually not considered. A major consequence of
guidelines was that antibiotic choices became
homogeneous at any one institution. This led to
the more rapid development of resistance.
The new model builds on the information
gleaned from the broad-based guidelines. The
new model looks at the speciﬁc organism in an
individual intensive care unit and facilitates in the
choice of empirical therapy based on local prob-
lems. In addition, guidelines may help to mini-
mise the duration of therapy. The shorter the T
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treatment, the less likely it is that resistant strains
will be selected. Although the initial antibiotic
choices may be more expensive, the de-escalation
of antibiotic use based on cost leads to a lower
overall cost with better survival than the current
model.
As the clinician treats the hospitalised patient
with infection, the choices are becoming more
limited. A more careful approach to the type and
duration of treatment has become necessary. With
this enlightened approach, we can hope to have
effective antibiotics for years to come.
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